KA/EN
Register
Medicines reference
Search
Search
Product

Paidocort

Favourites

Prednisolone · Aldo-Unión

1 form: solution. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form Dose Frequency Georgia
3 mg/ml, Solution No label dose in the reference yet - Georgia Yes, human
In force until 15 Jul 2029
Human (Ministry of Health, RAMA)
In the register: პაიდოკორტი 3 მგ/მლ, ორალური ხსნარი
№ რ-041566, რ-041566-1
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Paidocort 3 mg/ml, Solution

oral solution, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Systemic oral prednisolone as symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease with cause-directed care and monitoring
7.2/10
Good
vetman assessment

Paidocort

3 mg/ml, oral solution, human medicine
Assessed clinical scopeDog · Systemic oral prednisolone as symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease with cause-directed care and monitoring · By mouth
Care settingVeterinarian-directed home treatment with diagnosis-specific induction, scheduled reassessment, lowest-effective-dose taper and laboratory/clinical monitoring proportional to dose and duration
vetman score 7.2/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-041566, რ-041566-1 · Verified on 16 Oct 2026 Off-label use

A clinically powerful, well-established oral glucocorticoid in a dose-flexible liquid. Its value depends on a corticosteroid-responsive diagnosis, correct indication-specific dose, cause control, active monitoring and planned taper; human directions and excipient assumptions are not veterinary evidence.

Regulatory and scientific credibility7.5/10

Paidocort has an exact current AEMPS dossier and sourced Georgian/EU human authorisations; GB/US exact-brand negatives have same-endpoint positive controls. Veterinary prednisolone labels directly support species and oral route, but this flavoured liquid lacks veterinary authorisation and exact-product target-animal studies.

Clinical efficacy8.0/10

Oral prednisolone is an established intermediate-duration glucocorticoid with strong authorised-veterinary and guideline support across inflammatory and immune-mediated canine disease. Benefit can be high with correct diagnosis and dose, but remains symptomatic/adjunctive and disease-dependent.

Safety and tolerability5.5/10

Short selected courses are usually manageable, but polyuria/polydipsia, polyphagia, GI, skin/muscle, infectious, thrombotic and metabolic effects are dose- and duration-dependent. Chronic/high-dose use can cause iatrogenic hyperadrenocorticism and HPA suppression; abrupt withdrawal risks adrenal insufficiency and relapse.

Clinical practicality8.0/10

The 3 mg/ml liquid and supplied 3 ml/5 ml oral syringe support finer small-patient dosing and multi-step tapering than many tablets. The smallest syringe graduation is unpublished; strawberry acceptance, repeated measurement, bottle wastage and the two-month in-use limit remain practical constraints.

Full-course cost-effectiveness-

Price not assessed: no current Georgian clinic acquisition price and no diagnosis-specific full-course comparator dataset were verified.

Important safety and use flags

  • Do not use as a substitute for diagnosis or cause-directed treatment. Prednisolone can suppress inflammation while infection, neoplasia, endocrine disease or another underlying cause progresses.
  • Do not start immunosuppressive prednisolone with uncontrolled viral, fungal, bacterial or parasitic infection. Establish appropriate control first or concurrently when steroid benefit is essential.
  • Avoid concurrent NSAIDs and active gastrointestinal ulceration. Use an indication-appropriate washout when switching; overlap materially increases ulceration, perforation and bleeding risk.
  • Avoid or obtain specialist benefit-risk assessment with diabetes, hyperadrenocorticism, uncontrolled hypertension, glaucoma, osteoporosis, important cardiac/renal dysfunction, corneal ulceration or major thrombotic risk.
  • Do not give modified-live vaccines during immunosuppressive treatment. Review vaccination timing and immune response before starting and after stopping systemic prednisolone.
  • For more than a brief induction, monitor weight, appetite, drinking/urination, skin/muscle condition, blood pressure and infection; add CBC, chemistry, glucose, urine and culture according to dose, duration and patient risk.
  • Use the lowest effective dose and reassess early. Taper sustained supraphysiologic treatment according to disease control and exposure; abrupt withdrawal can cause adrenal insufficiency, hypotension, weakness, GI signs or relapse.
  • Review all medicines. Enzyme inducers may reduce effect, metabolism inhibitors may increase exposure, diuretics can worsen potassium loss, insulin requirements can change and other immunosuppressants increase infection risk.
  • Each ml contains 375 mg liquid maltitol plus methyl/propyl parabens. Maltitol may add osmotic gastrointestinal effects and parabens may cause delayed hypersensitivity. Xylitol is not declared; do not confuse the two sweeteners.
  • Veterinary palatability, the exact strawberry-flavour composition, smallest syringe graduation and reproductive safety are unverified. Confirm measurable volume, use within two months after opening, store below 25°C without refrigeration and document pregnancy/lactation benefit-risk.
Assessment sources
  1. Paidocort AEMPS SmPC2026
  2. VMD SPC 20262026
  3. Prednicortone 5 mg veterinary SPC2025
  4. Prednizol 5 mg UPD2026
  5. MSD corticosteroids2026
  6. MSD prednisolone dosing2026
  7. MSD airway glucocorticoids2026
  8. Canine glucocorticoid AEs2020
  9. Canine prednisolone HPA study2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Systemic oral prednisolone as symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease with cause-directed care and monitoring
7.5/10
Good
vetman assessment

Paidocort

3 mg/ml, oral solution, human medicine
Assessed clinical scopeCat · Systemic oral prednisolone as symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease with cause-directed care and monitoring · By mouth
Care settingVeterinarian-directed home treatment with diagnosis-specific induction, scheduled reassessment, lowest-effective-dose taper and laboratory/clinical monitoring proportional to dose and duration
vetman score 7.5/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-041566, რ-041566-1 · Verified on 16 Oct 2026 Off-label use

A clinically powerful, well-established oral glucocorticoid in a dose-flexible liquid. Its value depends on a corticosteroid-responsive diagnosis, correct indication-specific dose, cause control, active monitoring and planned taper; human directions and excipient assumptions are not veterinary evidence.

Regulatory and scientific credibility7.5/10

Paidocort has an exact current AEMPS dossier and sourced Georgian/EU human authorisations; GB/US exact-brand negatives have same-endpoint positive controls. Veterinary prednisolone labels directly support species and oral route, but this flavoured liquid lacks veterinary authorisation and exact-product target-animal studies.

Clinical efficacy8.5/10

Prednisolone is an established first-line systemic glucocorticoid for many feline corticosteroid-responsive diseases and is pharmacologically preferable to prednisone when hepatic activation is uncertain. Authorised veterinary products and feline oral disposition data support species and route, but benefit remains diagnosis-dependent.

Safety and tolerability6.0/10

Cats may show fewer classic chronic steroid signs than dogs, but infection, diabetes, skin fragility, heart-failure risk, GI ulceration and HPA suppression remain important. High-dose/prolonged treatment requires active monitoring and tapering; pregnancy and important comorbidity narrow the margin.

Clinical practicality8.5/10

The 3 mg/ml liquid can match common feline dose volumes and taper steps without tablet splitting, and the pack includes an oral syringe. The smallest graduation and feline taste acceptance are unverified; restraint, repeated dosing, bottle wastage and the two-month in-use limit still matter.

Full-course cost-effectiveness-

Price not assessed: no current Georgian clinic acquisition price and no diagnosis-specific full-course comparator dataset were verified.

Important safety and use flags

  • Do not use as a substitute for diagnosis or cause-directed treatment. Prednisolone can suppress inflammation while infection, neoplasia, endocrine disease or another underlying cause progresses.
  • Do not start immunosuppressive prednisolone with uncontrolled viral, fungal, bacterial or parasitic infection. Establish appropriate control first or concurrently when steroid benefit is essential.
  • Avoid concurrent NSAIDs and active gastrointestinal ulceration. Use an indication-appropriate washout when switching; overlap materially increases ulceration, perforation and bleeding risk.
  • Avoid or obtain specialist benefit-risk assessment with diabetes, hyperadrenocorticism, uncontrolled hypertension, glaucoma, osteoporosis, important cardiac/renal dysfunction, corneal ulceration or major thrombotic risk.
  • Do not give modified-live vaccines during immunosuppressive treatment. Review vaccination timing and immune response before starting and after stopping systemic prednisolone.
  • For more than a brief induction, monitor weight, appetite, drinking/urination, skin/muscle condition, blood pressure and infection; add CBC, chemistry, glucose, urine and culture according to dose, duration and patient risk.
  • Use the lowest effective dose and reassess early. Taper sustained supraphysiologic treatment according to disease control and exposure; abrupt withdrawal can cause adrenal insufficiency, hypotension, weakness, GI signs or relapse.
  • Review all medicines. Enzyme inducers may reduce effect, metabolism inhibitors may increase exposure, diuretics can worsen potassium loss, insulin requirements can change and other immunosuppressants increase infection risk.
  • Each ml contains 375 mg liquid maltitol plus methyl/propyl parabens. Maltitol may add osmotic gastrointestinal effects and parabens may cause delayed hypersensitivity. Xylitol is not declared; do not confuse the two sweeteners.
  • Veterinary palatability, the exact strawberry-flavour composition, smallest syringe graduation and reproductive safety are unverified. Confirm measurable volume, use within two months after opening, store below 25°C without refrigeration and document pregnancy/lactation benefit-risk.
Assessment sources
  1. Paidocort AEMPS SmPC2026
  2. VMD SPC 20262026
  3. Prednicortone 5 mg veterinary SPC2025
  4. Prednizol 5 mg UPD2026
  5. MSD corticosteroids2026
  6. MSD prednisolone dosing2026
  7. MSD airway glucocorticoids2026
  8. Feline oral prednisolone PK2013
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Prednisolone3 mg/ml
Formulation Type
Solution
Administration route
By mouth
Manufacturer
Aldo-Unión · Spain
Registration
Georgia Yes, human
In force until 15 Jul 2029
Human (Ministry of Health, RAMA)
In the register: პაიდოკორტი 3 მგ/მლ, ორალური ხსნარი
№ რ-041566, რ-041566-1
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Use a diagnosis-specific veterinary prednisolone regimen, not the human Paidocort schedule. Authorised veterinary labels give two distinct oral ranges in dogs and cats: 0.1–2 mg/kg/day for anti-inflammatory/antiallergic treatment and 0.5–4 mg/kg/day as a starting range for inflammatory/immune-mediated disease. At 3 mg/ml these equal 0.033–0.667 ml/kg/day and 0.167–1.333 ml/kg/day. Do not merge them into one universal range; select the indication, lowest effective dose, timing and taper. Confirm that the calculated volume is measurable with the supplied syringe.

Prednisolone: No dose supported by a publicly verifiable source yet

Known Contraindications

  • Critical
    An uncontrolled viral, fungal, or parasitic infection is an absolute contraindication. The parasitic-infection restriction is specified on the Prednicare label.
  • Critical
    Diabetes mellitus is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical
    Hyperadrenocorticism is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical
    Osteoporosis is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical
    Corneal ulceration is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical
    Glaucoma is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical
    Hypersensitivity to prednisolone or any excipient is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical
    Burn injury is listed as a contraindication on the Prednicortone label but not on the other two reviewed labels.
    Sources: Product label
  • Critical
    Cataract is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical
    Hypocalcaemia is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical
    Hypertension is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical
    Pancreatitis is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical
    A poorly healing wound or fracture is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical
    General immunodeficiency is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical
    Gastrointestinal ulceration is an absolute contraindication on all three reviewed labels. Concomitant corticosteroid and NSAID treatment further increases the risk of ulceration; see the interaction warnings.
    Sources: Product label
  • Critical
    cardiac or renal dysfunction
    Sources: Product label
  • Critical
    Severe renal impairment is an absolute contraindication on the Prednicare label.
    Sources: Product label
  • Critical
    Do not use during pregnancy. Some corticosteroid products specify this restriction for the final third of gestation.
  • Warning
    Use in growing animals carries a risk of growth retardation, suppression of bone growth, and damage to the bone matrix.
  • Warning
    Do not use with a live attenuated vaccine because corticosteroids suppress the immune response to vaccination. The Prednicortone label also prohibits use within 2 weeks after vaccination.
  • Warning
    very rare

Known Drug Interactions

  • Contraindicated Meloxicam + Prednisolone
    Concomitant use of corticosteroids and non-steroidal anti-inflammatory drugs can worsen gastrointestinal ulceration.
    Recommendation: Do not administer together. Observe an appropriate washout period when switching and monitor for melena, vomiting, and reduced appetite.
    Sources: Product label
  • Contraindicated Robenacoxib + Prednisolone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Prednisolone + Insulin glargine
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Prednisolone + Insulin human
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Furosemide + Prednisolone
    Concurrent use with drugs affecting electrolyte balance (corticosteroids, other diuretics, amphotericin B, cardiac glycosides) requires careful monitoring.
    Recommendation: Monitor electrolytes, particularly potassium. Check periodically during prolonged combination therapy.
    Sources: VMD SPC · VMD
  • Major warning Carprofen + Prednisolone
    Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.
    Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
    Sources: FDA

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (31 more) Hide additional products

Same active ingredients 2

Same therapeutic group 29

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗